High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab – a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO) - Tero Ylisaukko-Oja, Jaakko Aaltonen, Heikki Nuutinen, Timo Blomster, Airi Jussila, Markku Pajala, Kimmo Salminen, Veikko Moilanen, Kalle Hakala, Mikko Kellokumpu, Kari Toljamo, Henna Rautiainen, Juha Kuisma, Markku Peräaho, Pauliina Molander - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

Taylor and Francis Group, Scandinavian Journal of Gastroenterology, 2(53), p. 158-167, 2017

DOI: 10.1080/00365521.2017.1416160

Links

Tools

Export citation

Search in Google Scholar

High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab – a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)

Journal article published in 2017 by Tero Ylisaukko-Oja, Jaakko Aaltonen, Heikki Nuutinen, Timo Blomster, Airi Jussila, Markku Pajala, Kimmo Salminen, Veikko Moilanen, Kalle Hakala, Mikko Kellokumpu, Kari Toljamo, Henna Rautiainen, Juha Kuisma, Markku Peräaho, Pauliina Molander and other authors.

Distributing this paper is prohibited by the publisher

Distributing this paper is prohibited by the publisher

Full text: Unavailable

Red circle

Preprint: archiving forbidden

Orange circle

Postprint: archiving restricted

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO